All Updates

All Updates

icon
Filter
FDA approval
Hinova Pharmaceuticals receives FDA Fast Track Designation for HP518 breast cancer drug candidate
Precision Medicine
Jul 5, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jul 5, 2024

Hinova Pharmaceuticals receives FDA Fast Track Designation for HP518 breast cancer drug candidate

FDA approval

  • Hinova Pharmaceuticals has received the US FDA Fast Track Designation for its drug candidate, HP518, for the treatment of Androgen-receptor positive (AR+) triple-negative breast cancer (TNBC).

  • HP518 is an oral AR PROTAC protein degrader that degrades wild-type AR and clinically relevant AR ligand-binding domain (LBD) mutants, including L702H. It is currently in Phase I/II clinical trials conducted in China for patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC). With the Fast Track Designation, the company plans to accelerate the development and commercialization of HP518 to improve patient outcomes.

  • Hinova Pharmaceuticals is a biopharmaceutical company based in China,  specializing in developing drugs using PROTAC (proteolysis-targeting chimera) and deuteration technology. The company focuses on creating therapeutics for oncology and metabolic diseases. Its pipeline includes several drug candidates, such as HC-1119 for castration-resistant prostate cancer, HP501 for hyperuricemia, and HP518, an androgen receptor degrader. Hinova's research platforms include targeted drug discovery and validation, as well as lead compound optimization screening​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.